Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

​ Conditions: HNSCC,Larynx, Pharynx and Oral Cavity; Squamous Cell Carcinoma; Head and Neck Cancer; Head and Neck Surgery

Interventions: Drug: Panitumumab-IRDye800; Drug: [18F]NOTA-ABY-030

Sponsors: Vanderbilt-Ingram Cancer Center

Not yet recruiting Conditions: HNSCC,Larynx, Pharynx and Oral Cavity; Squamous Cell Carcinoma; Head and Neck Cancer; Head and Neck Surgery
Interventions: Drug: Panitumumab-IRDye800; Drug: [18F]NOTA-ABY-030
Sponsors: Vanderbilt-Ingram Cancer Center
Not yet recruiting